ReviewUse of Desmopressin (cas 16679-58-6) in Hyponatremia: Foe and Friend
-
Add time:09/06/2019 Source:sciencedirect.com
Use of Desmopressin (cas 16679-58-6) (1-deamino-8-d-arginine vasopressin; DDAVP), a synthetic vasopressin receptor agonist, has expanded in recent years. Desmopressin leads to renal water retention, and iatrogenic hyponatremia may result if fluid intake is not appropriately restricted. It is common practice to stop a medication that is causing toxicity, and this advice is promulgated in Micromedex, which suggests withholding desmopressin if hyponatremia occurs. If intravenous saline solution is administered and desmopressin is withheld at the same time, rapid changes in serum sodium levels may result, which puts the patient at risk for demyelinating lesions. In the management of desmopressin-associated hyponatremia with neurologic symptoms, the drug should not be withheld despite the presence of hyponatremia. The medication should be continued while administering intravenous hypertonic saline solution. Desmopressin is also used to minimize water excretion during the correction of hyponatremia during water diuresis. When treating hyponatremia, clinicians should monitor closely to avoid free-water diuresis. To prevent ongoing water losses in urine and overly rapid “autocorrection” of serum sodium level, desmopressin can be given to reduce free-water losses. These treatment recommendations are the authors’ perspective from previously published work and personal clinical experience.
We also recommend Trading Suppliers and Manufacturers of Desmopressin (cas 16679-58-6). Pls Click Website Link as below: cas 16679-58-6 suppliers
Prev:Full length articleSelenide effect for oxidation stability of the organic solvent-free copper sulfide Nano-particles and its organic photodiode application
Next:Constipation in nocturnal enuresis may interfere Desmopressin (cas 16679-58-6) management success) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Clinical Research StudyOutcomes in Severe Hyponatremia Treated With and Without Desmopressin (cas 16679-58-6)10/01/2019
- Neuro-urologyLow-dose Desmopressin (cas 16679-58-6) Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria09/27/2019
- Clinical studyCohort analysis of Desmopressin (cas 16679-58-6) effect on hematoma expansion in patients with spontaneous intracerebral hemorrhage and documented pre-ictus antiplatelet use09/26/2019
- ‘Frequently recurring’ nocturnal polyuria is predictive of response to Desmopressin (cas 16679-58-6) in monosymptomatic nocturnal enuresis in childhood09/25/2019
- ReviewOral Desmopressin (cas 16679-58-6) in nocturia with benign prostatic hyperplasia: A systematic review of the literature09/24/2019
- Original ContributionDesmopressin (cas 16679-58-6)/indomethacin combination efficacy and safety in renal colic pain management: A randomized placebo controlled trial09/10/2019
- 62 - Desmopressin (cas 16679-58-6) (DDAVP)09/09/2019
- Meloxicam-Desmopressin (cas 16679-58-6) drug-drug interaction producing hyponatremia09/08/2019
- Constipation in nocturnal enuresis may interfere Desmopressin (cas 16679-58-6) management success09/07/2019
-
Health and Chemical more >
-
Related Products